{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:22:33Z","timestamp":1793906553467,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune polyendocrine syndrome type-1 (APS-1) is caused by mono- or biallelic loss-of-function variants of the autoimmune regulator gene <jats:italic>AIRE<\/jats:italic> underlying early-onset multiorgan autoimmunity and the production of neutralizing autoantibodies against cytokines, accounting for mucosal candidiasis and viral diseases. Medical intervention is essential to prevent or attenuate autoimmune manifestations. Ruxolitinib is a JAK inhibitor approved for use in several autoimmune conditions. It is also used off-label to treat autoimmune manifestations of a growing range of inborn errors of immunity. We treated three APS-1 patients with ruxolitinib and followed them for at least 30\u00a0months. Tolerance was excellent, with no medical or biological adverse events. All three patients had remarkably positive responses to ruxolitinib for alopecia, nail dystrophy, keratitis, mucosal candidiasis, steroid-dependent autoimmune hepatitis, exocrine pancreatic insufficiency, renal potassium wasting, hypoparathyroidism, and diabetes insipidus. JAK inhibitors were therefore considered an effective treatment in three patients with APS-1. Our observations suggest that JAK\/STAT pathways are involved in the pathogenesis of APS-1 autoimmune manifestations. They also suggest that JAK inhibitors should be tested in a broader range of APS-1 patients.<\/jats:p>","DOI":"10.1007\/s10875-023-01629-x","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T09:02:35Z","timestamp":1702976555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-0198","authenticated-orcid":false,"given":"Romain","family":"L\u00e9vy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polivka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Stoupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Talbotec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"4","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ng1297-393","volume":"17","author":"K Nagamine","year":"1997","unstructured":"Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17(4):393\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ng1297-399","volume":"17","author":"Finnish-German APECED Consortium","year":"1997","unstructured":"Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17(4):399\u2013403.","journal-title":"Nat Genet"},{"issue":"6","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.immuni.2015.04.021","volume":"42","author":"BE Oftedal","year":"2015","unstructured":"Oftedal BE, Hellesen A, Erichsen MM, et al. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 2015;42(6):1185\u201396.","journal-title":"Immunity"},{"key":"1629_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye ES, Anderson MS, K\u00e4mpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378:1132\u201341.","journal-title":"N Engl J Med"},{"issue":"5","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10875-015-0176-y","volume":"35","author":"K Kisand","year":"2015","unstructured":"Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol. 2015;35(5):463\u201378.","journal-title":"J Clin Immunol"},{"key":"1629_CR6","doi-asserted-by":"publisher","first-page":"723532","DOI":"10.3389\/fped.2021.723532","volume":"9","author":"EMN Ferr\u00e9","year":"2021","unstructured":"Ferr\u00e9 EMN, Schmitt MM, Lionakis MS. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Front Pediatr. 2021;9:723532.","journal-title":"Front Pediatr"},{"issue":"5597","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1126\/science.1075958","volume":"298","author":"MS Anderson","year":"2002","unstructured":"Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395\u2013401.","journal-title":"Science"},{"issue":"2","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.20091983","volume":"207","author":"A Puel","year":"2010","unstructured":"Puel A, D\u00f6ffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291\u20137.","journal-title":"J Exp Med"},{"key":"1629_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","volume":"207","author":"K Kisand","year":"2010","unstructured":"Kisand K, B\u00f8e Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207:299\u2013308.","journal-title":"J Exp Med"},{"issue":"7","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","volume":"3","author":"A Meager","year":"2006","unstructured":"Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. Plos Med. 2006;3(7):e289.","journal-title":"Plos Med"},{"issue":"11","key":"1629_CR11","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1210\/jc.2008-0935","volume":"93","author":"A Meloni","year":"2008","unstructured":"Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008;93(11):4389\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1056\/NEJM199006283222601","volume":"322","author":"P Ahonen","year":"1990","unstructured":"Ahonen P, Myll\u00e4rniemi S, Sipil\u00e4 I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322(26):1829\u201336.","journal-title":"N Engl J Med"},{"issue":"1","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cen.12087","volume":"79","author":"N Kluger","year":"2013","unstructured":"Kluger N, Jokinen M, Krohn K, Ranki A. What is the burden of living with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) in 2012? A health-related quality-of-life assessment in Finnish patients. Clin Endocrinol (Oxf). 2013;79(1):134\u201341.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1629_CR14","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370."},{"key":"1629_CR15","doi-asserted-by":"crossref","unstructured":"Bastard P, Orlova E, Sozaeva L, L\u00e9vy R, James A, Schmitt MM, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218.","DOI":"10.1084\/jem.20210554"},{"key":"1629_CR16","doi-asserted-by":"crossref","unstructured":"Casanova J-L, Anderson MS. Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. J Clin Invest. 2023;133:e166283.","DOI":"10.1172\/JCI166283"},{"issue":"3","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.31421","volume":"73","author":"DM Chascsa","year":"2021","unstructured":"Chascsa DM, Ferr\u00e9 EMN, Hadjiyannis Y, et al. APECED-Associated hepatitis: Clinical, biochemical, histological and treatment data from a large predominantly American cohort. Hepatology. 2021;73(3):1088\u2013104.","journal-title":"Hepatology"},{"issue":"495","key":"1629_CR18","doi-asserted-by":"publisher","first-page":"eaav5597","DOI":"10.1126\/scitranslmed.aav5597","volume":"11","author":"EMN Ferr\u00e9","year":"2019","unstructured":"Ferr\u00e9 EMN, Break TJ, Burbelo PD, et al. Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci Transl Med. 2019;11(495):eaav5597.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10875-020-00914-3","volume":"41","author":"E Sarfati","year":"2021","unstructured":"Sarfati E, Hadjadj J, Fusaro M, et al. Life-Saving, Dose-Adjusted, Targeted Therapy in a Patient with a STAT3 Gain-of-Function Mutation. J Clin Immunol. 2021;41(4):807\u201310.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1629_CR21","unstructured":"Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V, et al. JAK-inhibitor treatment for inborn errors of JAK\/STAT signaling: An ESID and EBMT IEWP retrospective study. J Allergy Clin Immunol. 2023;S0091\u20136749(23):01390\u20138."},{"issue":"6","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10875-023-01500-z","volume":"43","author":"M-L Fr\u00e9mond","year":"2023","unstructured":"Fr\u00e9mond M-L, Hully M, Fournier B, et al. JAK Inhibition in Aicardi-Gouti\u00e8res syndrome: A monocentric multidisciplinary real-world approach study. J Clin Immunol. 2023;43(6):1436\u201347.","journal-title":"J Clin Immunol"},{"issue":"13","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"e88782","DOI":"10.1172\/jci.insight.88782","volume":"1","author":"EMN Ferre","year":"2016","unstructured":"Ferre EMN, Rose SR, Rosenzweig SD, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016;1(13):e88782.","journal-title":"JCI Insight"},{"issue":"8","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1210\/jc.2016-1821","volume":"101","author":"\u00d8 Bruserud","year":"2016","unstructured":"Bruserud \u00d8, Oftedal BE, Landegren N, et al. A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab. 2016;101(8):2975\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1629_CR25","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","volume":"73","author":"C Liu","year":"2021","unstructured":"Liu C, Kieltyka J, Fleischmann R, Gadina M, O\u2019Shea JJ. A decade of JAK inhibitors: What have we learned and what may be the future? Arthritis Rheumatol. 2021;73(12):2166\u201378.","journal-title":"Arthritis Rheumatol"},{"key":"1629_CR26","doi-asserted-by":"publisher","first-page":"108851","DOI":"10.1016\/j.clim.2021.108851","volume":"231","author":"I Hetem\u00e4ki","year":"2021","unstructured":"Hetem\u00e4ki I, Laakso S, V\u00e4limaa H, et al. Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin Immunol. 2021;231:108851.","journal-title":"Clin Immunol"},{"issue":"530","key":"1629_CR27","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","volume":"12","author":"S Adam","year":"2020","unstructured":"Adam S, Simon N, Steffen U, et al. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med. 2020;12(530):eaay4447.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","volume":"148","author":"Y Luo","year":"2021","unstructured":"Luo Y, Alexander M, Gadina M, O\u2019Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol. 2021;148(4):911\u201325.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01629-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:17:15Z","timestamp":1706692635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01629-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01629-x","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patients or their parents (for minors), in accordance with World Medical Association rules, the Helsinki Declaration, and EU directives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}